PSMA Radiopharmaceutical Linker Design for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging and treatment methods for prostate cancer, particularly androgen-independent and metastatic forms, lack effective agents that can selectively target prostate-specific membrane antigen (PSMA) for accurate detection and therapy.
Innovation Solution
Development of novel radiopharmaceuticals with specific ligands that interact with PSMA, incorporating structural modifications in the linker region to enhance tumor targeting properties and pharmacokinetics, allowing for improved detection and treatment of prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current imaging and treatment methods (CT, MR, ultrasound) are used for prostate cancer detection and therapy, then general imaging capability is provided, but selective targeting of PSMA is lacking and treatment effectiveness for androgen-independent and metastatic forms is insufficient
Solution Approach 1:
The patent applies local quality by designing radiopharmaceuticals with specific ligands that selectively bind to PSMA receptors on prostate cancer cells. The compounds in Formula (Ia) and (Ib) contain specific structural features (glutamate-urea-lysine motif) that provide localized recognition and binding affinity for PSMA, enabling selective targeting of prostate cancer tissue while leaving other tissues unaffected.
Solution Approach 2:
The patent employs parameter changes by modifying the linker region structures in the radiopharmaceutical compounds to optimize their pharmacokinetic properties and binding characteristics. Different linker configurations (varying in length, flexibility, and chemical composition) are used to adjust the compounds' affinity for PSMA, their stability in circulation, and their ability to penetrate tumor tissue, thereby improving effectiveness against resistant and metastatic forms.
2Reliability
If radiopharmaceuticals with modified linker regions are developed to enhance tumor targeting, then tumor targeting properties and retention are improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the radiopharmaceutical molecule into distinct functional modules: a PSMA-binding motif (glutamate-urea-lysine), a variable linker region, and a radionuclide chelator. This modular design allows independent optimization of each component - the linker can be modified to improve tumor targeting without changing the PSMA-binding motif or chelator, thereby managing complexity through functional decomposition.
Solution Approach 2:
The linker region serves as an intermediary component that connects the PSMA-binding motif to the radionuclide chelator. By placing the variable linker in this intermediary position, the patent allows optimization of tumor penetration and retention properties without affecting the critical PSMA-binding interaction or the radionuclide complexation, thus isolating the complexity to a non-critical intermediate region.
3Measurement precision
If radiopharmaceuticals are designed for enhanced tumor targeting, then detection accuracy and therapeutic efficacy improve, but kidney uptake increases causing harmful side effects
Solution Approach 1:
The patent applies the taking out principle by extracting and modifying the linker region to reduce renal accumulation. The optimized linkers improve tumor-specific retention while decreasing clearance through the kidneys, effectively separating the tumor-targeting function from the renal excretion pathway. This reduces the harmful concentration buildup in kidney tissue while maintaining high detection accuracy and therapeutic efficacy in prostate cancer.
Data Source
AI summary
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).